January 17, 2025

FDA Chief Warns of Online Drug Risks

Outgoing FDA Commissioner raises concerns about safety of online-purchased compounded weight loss meds, highlighting challenges faced by the FDA, amidst contrasting views from nominee for Health and Human Services Secretary.

Reuters

January 17, 2025

Trial: High-Dose Semaglutide Cuts Weight 20.7%

Novo Nordisk's high-dose semaglutide trial demonstrates a 20.7% weight reduction in overweight patients with obesity, promising new advancements in the treatment of obesity and diabetes.

Reuters

January 16, 2025

Vertigo, Emesis, Auditory Impairment: What's Your Diagnosis?

A patient presents with sudden-onset right-sided otalgia accompanied by vertigo, emesis, and auditory impairment. Your otoscope reveals an unexpected finding. What's your diagnosis?

Conexiant

January 16, 2025

Algorithm Improves Diagnosis of Uterine Lesions

"The preoperative 3-class diagnostic algorithm and risk class system can stratify women according to risk of malignancy."

Conexiant

January 16, 2025

Exercise Therapy as Candidate Anticancer Strategy

Lee Jones, PhD, Head of the Exercise Oncology Program at Memorial Sloan Kettering Cancer Center, shared findings from an early-phase clinical trial to determine the feasibility, safety, and tumor biol...

The ASCO Post

January 16, 2025

New XLH Guidelines Shift Primary Therapy to Burosumab

"Burosumab treatment normalized ALP serum levels in about 80% of both pediatric and adolescent cohorts, suggesting a substantial improvement of rickets in these patients," report authors of comprehensive new evidence-based recommendations for X-linked hypophosphatemia management.

Conexiant

January 16, 2025

Bone Density Risks in Cancer Survivors

Discover how cancer treatments, lifestyle factors, and comorbidities contribute to long-term bone mineral density deficits in childhood cancer survivors.

Conexiant

January 16, 2025

FDA Clears Phase 2 Trial: Lorundrostat for OSA-Hypertension

Mineralys Therapeutics receives FDA clearance for a phase II clinical trial investigating lorundrostat, an aldosterone synthase inhibitor, in patients with moderate-to-severe obstructive sleep apnea and hypertension.

Conexiant

January 15, 2025

FDA to Revoke Red No. 3

Red No. 3 is found in many popular food items, including Pop Tarts, Dole Fruit Packs, Double Bubble Gum, Peeps, and more.

Conexiant